Loading...
•
Mar 31, 2025
Globus Medical Q1 2025 Earnings Report
Reported First Quarter 2025 Financial Results
Key Takeaways
Globus Medical reported a slight decrease in net sales for Q1 2025 compared to the prior year, primarily due to softer Enabling Technology sales and international order timing, offset by strength in the US spine business. The company achieved GAAP net income and positive GAAP and non-GAAP EPS, alongside record Q1 free cash flow and a return to debt-free status.
Worldwide net sales decreased by 1.4% to $598.1 million in Q1 2025.
GAAP net income was $75.5 million for the quarter.
GAAP diluted EPS was $0.54 and non-GAAP diluted EPS was $0.68.
The company delivered record Q1 free cash flow of $141.2 million and paid off remaining debt from the NuVasive merger.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company reaffirms its full-year 2025 revenue guidance but updated its non-GAAP fully diluted earnings per share guidance downwards.
Positive Outlook
- Reaffirms full-year 2025 revenue guidance range of $2.80 to $2.90 billion.
- Continued strong performance observed in April.
- Confidence in driving above-market revenue growth.
- Commitment to investing in innovative and clinically advanced products and solutions.
- Steadfast in vision for the future.
Challenges Ahead
- Updated non-GAAP fully diluted earnings per share guidance to a range of $3.00 to $3.30.
- This new EPS guidance range is a decrease from the prior guidance of $3.10 to $3.40.
- Softer Enabling Technology deal closures impacted Q1 results.
- Temporary integration related supply chain disruption impacted Q1 results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...